EGFR and non-small cell lung carcinoma: A Phase 1 Open-label Prospective Cohort Trial of CUR Plus Tyrosine Kinase Inhibitors for Epidermal Growth Factor Receptor (EGFR)-Mutant Advanced Non-small Cell Lung Cancer is the title of a preliminary clinical trial (NCT02321293) [112] in which patients daily receive the drugs GEF and ERL and Longvida® Optimized CUR for eight weeks.